Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
QMS Medical Allied Services is an integrated healthcare company that markets, distributes and services medical devices and runs Patient Support Programs (PSP), B2B health camps and an e-commerce platform, combining product distribution including Q-Devices with technology-enabled patient journey services across India.
Financially, the company delivered 9MFY26 revenue of Rs 128.5 crore, up 15% YoY, with EBITDA of Rs 20.1 crore and PAT of Rs 9.9 crore; however Q3FY26 showed sequential moderation with revenue of Rs 37.3 crore and PAT of Rs 3.2 crore, highlighting short-term volatility amid sustained nine‑month growth.
QMS operates a proprietary AWS-hosted, ISO 9001 certified digital health platform that integrates CRM, tele- and field-intervention and AI analytics to manage over one million patients and 350,000+ healthcare professionals, creating a differentiated, scalable technology moat for its PSP and pharma engagement offerings.
Strategically, the company has expanded its services footprint through the Saarathi Healthcare acquisition, scaled the Q-Devices owned brand since 2023, and gained eGrameen portal access to penetrate rural markets—moves that position QMS to convert device distribution into recurring PSP revenues and rural market share.
Balance sheet and cashflow trends show improving profitability and strong multi-year CAGR in revenue and EBITDA, but rising short-term borrowings and working capital swings remain notable; management emphasizes disciplined execution to sustain margin profile while scaling PSPs and device sales.
Healthcare Equipment & Supplies
Medical Equipment & Supplies
188 Cr
Low Risk
18.5
41.7
0.4
1.8
111.00
68.95
Sales CAGR
Profit CAGR
ROE
ROCE
QMS Medical Allied Services Ltd (QMSMEDI) is currently trading at 109.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
QMS Medical Allied Services is an integrated healthcare company that markets, distributes and services medical devices and runs Patient Support Programs (PSP), B2B health camps and an e-commerce platform, combining product distribution including Q-Devices with technology-enabled patient journey services across India. Financially, the company delivered 9MFY26 revenue of Rs 128.5 crore, up 15% YoY, with EBITDA of Rs 20.1 crore and PAT of Rs 9.9 crore; however Q3FY26 showed sequential moderation with revenue of Rs 37.3 crore and PAT of Rs 3.2 crore, highlighting short-term volatility amid sustained nine‑month growth. QMS operates a proprietary AWS-hosted, ISO 9001 certified digital health platform that integrates CRM, tele- and field-intervention and AI analytics to manage over one million patients and 350,000+ healthcare professionals, creating a differentiated, scalable technology moat for its PSP and pharma engagement offerings. Strategically, the company has expanded its services footprint through the Saarathi Healthcare acquisition, scaled the Q-Devices owned brand since 2023, and gained eGrameen portal access to penetrate rural markets—moves that position QMS to convert device distribution into recurring PSP revenues and rural market share. Balance sheet and cashflow trends show improving profitability and strong multi-year CAGR in revenue and EBITDA, but rising short-term borrowings and working capital swings remain notable; management emphasizes disciplined execution to sustain margin profile while scaling PSPs and device sales.
Over the past 52 weeks, QMS Medical Allied Services Ltd has traded between a low of ₹68.95 and a high of ₹111.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
QMS Medical Allied Services Ltd has a market capitalization of approximately 187.57. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
QMS Medical Allied Services Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 187.57 Cr, QMS Medical Allied Services Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
QMS Medical Allied Services Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of QMS Medical Allied Services Ltd is 18.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
8
Neutral
1
Bullish
5
Bearish
8
Neutral
1
Bullish
37
Bearish
0
Neutral
0
Bullish
32
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
159.00 | 305 Cr | 59.73 | 4.39 | 0.00 | 7.35 | 14.27 | 6.24 | ||
126.00 | 304 Cr | 33.59 | 3.06 | 0.41 | 9.10 | 12.59 | 7.84 | ||
238.70 | 227 Cr | 109.27 | 1.26 | 0.00 | 1.15 | 3.42 | 1.06 | ||
109.40 | 188 Cr | 18.52 | 1.80 | 0.52 | 9.72 | 12.87 | 5.60 | ||
130.00 | 165 Cr | 33.48 | 2.55 | 0.00 | 7.67 | 12.12 | 7.09 | ||
71.00 | 101 Cr | 15.24 | 1.85 | 0.00 | 12.17 | 15.03 | 8.36 | ||
148.55 | 82 Cr | 15.45 | 2.23 | 0.00 | 12.67 | 18.00 | 11.17 | ||
| Median: 7 Co. | — | 130.00 | 188 Cr | 33.48 | 2.23 | 0.00 | 9.10 | 12.87 | 7.09 |
Listing Migration
NSE approved migration of QMS Medical Allied Services Ltd from the NSE Emerge (SME) platform to the Main Board effective June 18, 2026; 19,337,443 equity shares (Rs.10) to list under symbol QMSMEDI and SME trading to be suspended.
Listing Migration
NSE has approved migration of QMS Medical Allied Services Limited (symbol: QMSMEDI) from the SME Emerge platform to the Main Board, effective June 18, 2026; 19,337,443 equity shares to be listed and SME trading suspended.
